Ignite Creation Date:
2025-12-25 @ 2:37 AM
Ignite Modification Date:
2026-01-08 @ 3:44 AM
Study NCT ID:
NCT04317534
Status:
RECRUITING
Last Update Posted:
2025-05-04
First Post:
2020-03-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Sponsor:
Greg Durm, MD
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-05-05
Start Date Type:
ACTUAL
Primary Completion Date:
2026-04-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-04-01
Completion Date Type:
ESTIMATED
First Submit Date:
2020-03-19
First Submit QC Date:
None
Study First Post Date:
2020-03-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-05-01
Last Update Post Date:
2025-05-04
Last Update Post Date Type:
ACTUAL